A retrospective study on the efficacy and safety of continuous subcutaneous hydromorphone titration for cancer pain

A retrospective study on the efficacy and safety of continuous subcutaneous hydromorphone titration for cancer pain - A retrospective study on continuous subcutaneous hydromorphone titration for cancer pain

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000046399

Enrollment

Registered

2021-12-16

Start date

2021-12-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate or severe, uncontrollable cancer pain.

Interventions

Continuous subcutaneous injection of hydromorphone.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Moderate or severe, uncontrollable cancer pain.

Exclusion criteria

Exclusion criteria: None.

Design outcomes

Primary

Measure	Time frame
Completion rate of titration.	—

Secondary

Measure	Time frame
Time to completion of titration; response rate; effect on other symptoms including dyspnea; adverse events.	—

Countries

Japan

Contacts

Public ContactTatsuma Sakaguchi

The Tazuke Kofukai Medical Research Institute, Kitano Hospital Department of palliative care

t-sakaguchi@kitano-hp.or.jp06-6312-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026